Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of mepolizumab IV in hypereosinophilic syndromes
2004-000929-30Phase 3Completed
- Sponsor
- GSK
- Start
- May 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Mepolizumab 750 mg IV with Placebo IV (2 arms). Primary endpoints: Corticosteroid-reduction and -sparing effect, Control of clinical signs and symptoms of HES and 1 more. Started May 2005; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2004-000929-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000929-30.